Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients.  Ozempic, a drug approved for Type 2 diabetes, cardiovascular disease and kidney disease, has a list price of $997. Wegovy, which is indicated for weight loss, cardiovascular disease and liver disease, costs $1,349 for a four-week supply. 

As of Aug. 18, all strengths of both GLP-1 medications are available for $499 per month for self-paying patients. More than 70,000 U.S. retail pharmacies are participating in the offering, according to GoodRx and Novo Nordisk.   The post Novo Nordisk halves Ozempic price for self-paying patients appeared first on Becker's Hospital Review | Healthcare News & Analysis.

See Full Page